The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Practical considerations for switching from ruxolitinib to momelotinib in patients with MF
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the practical considerations for switching from ruxolitinib to momelotinib in patients with myelofibrosis (MF). Dr Bose notes that momelotinib’s similar mechanism of action and short half-life allow for a seamless transition from ruxolitinib, as demonstrated in the SIMPLIFY-1 (NCT01969838) trial. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
